David Wheeler talks about the findings of the FIGARO trial, the use of finerenone in people with type 2 diabetes, and how this may fit with SGLT2 inhibitors (7:22).
09-15-2021 | ESC 2021 | Conference coverage | Video
09-15-2021 | ESC 2021 | Conference coverage | Video
David Wheeler talks about the findings of the FIGARO trial, the use of finerenone in people with type 2 diabetes, and how this may fit with SGLT2 inhibitors (7:22).